Efficacy and tolerability of brivaracetam in patients with intellectual disability and epilepsy

[1]  M. Maguire,et al.  Adjunctive brivaracetam in focal and generalized epilepsies: A single-center open-label prospective study in patients with psychiatric comorbidities and intellectual disability , 2019, Epilepsy & Behavior.

[2]  F. Kerling,et al.  Behavioural changes in patients with intellectual disability treated with brivaracetam , 2018, Acta neurologica Scandinavica.

[3]  J Wagner,et al.  Brivaracetam in the Treatment of Patients with Epilepsy—First Clinical Experiences , 2018, Front. Neurol..

[4]  P. Klein,et al.  A review of the pharmacology and clinical efficacy of brivaracetam , 2018, Clinical pharmacology : advances and applications.

[5]  Patrick Kwan,et al.  Treatment Outcomes in Patients With Newly Diagnosed Epilepsy Treated With Established and New Antiepileptic Drugs: A 30-Year Longitudinal Cohort Study , 2017, JAMA neurology.

[6]  M. Brodie,et al.  Brivaracetam: a novel antiepileptic drug for focal-onset seizures , 2017, Therapeutic Advances in Neurological Disorders.

[7]  F. Rosenow,et al.  Postmarketing experience with brivaracetam in the treatment of epilepsies: A multicenter cohort study from Germany , 2017, Epilepsia.

[8]  Eric C. Nemec,et al.  Brivaracetam (Briviact): A Novel Adjunctive Therapy for Partial-Onset Seizures. , 2017, P & T : a peer-reviewed journal for formulary management.

[9]  C. Bien,et al.  Brivaracetam as adjunctive therapy for the treatment of partial-onset seizures in patients with epilepsy: the current evidence base , 2016, Therapeutic advances in neurological disorders.

[10]  Josemir W Sander,et al.  Managing anti‐epileptic drug treatment in adult patients with intellectual disability: a serious conundrum , 2016, European journal of neurology.

[11]  M. Silvestrini,et al.  Brivaracetam add-on for refractory focal epilepsy , 2016, Neurology.

[12]  M. Sperling,et al.  A randomized, double‐blind, placebo‐controlled, multicenter, parallel‐group study to evaluate the efficacy and safety of adjunctive brivaracetam in adult patients with uncontrolled partial‐onset seizures , 2015, Epilepsia.

[13]  Chris Hatton,et al.  Prevalence of epilepsy among people with intellectual disabilities: A systematic review , 2015, Seizure.

[14]  P. Ryvlin,et al.  Adjunctive brivaracetam in adults with uncontrolled focal epilepsy: Results from a double‐blind, randomized, placebo‐controlled trial , 2014, Epilepsia.

[15]  P. Kwan,et al.  Adjunctive brivaracetam for uncontrolled focal and generalized epilepsies: Results of a phase III, double‐blind, randomized, placebo‐controlled, flexible‐dose trial , 2014, Epilepsia.

[16]  M. Sperling,et al.  Brivaracetam as adjunctive treatment for uncontrolled partial epilepsy in adults: A phase III randomized, double‐blind, placebo‐controlled trial , 2014, Epilepsia.

[17]  Christian Bottomley,et al.  Estimation of the burden of active and life-time epilepsy: A meta-analytic approach , 2010, Epilepsia.

[18]  A. Marson,et al.  Pharmacological interventions for epilepsy in people with intellectual disabilities. , 2015, The Cochrane database of systematic reviews.

[19]  S. Bhaumik,et al.  Epilepsy in adults with intellectual disabilities: Prevalence, associations and service implications , 2006, Seizure.

[20]  V. Horstmann,et al.  Seizure freedom with different therapeutic regimens in intellectually disabled epileptic patients , 2005, Seizure.

[21]  S. Johannessen,et al.  Levetiracetam in adult patients with and without learning disability: focus on behavioral adverse effects , 2004, Epilepsy & Behavior.